Full Text
The Full Text of this article is available as a PDF (118.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bryant J., Clegg A., Milne R. Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost? J Neurol Neurosurg Psychiatry. 2001 May;70(5):574–579. doi: 10.1136/jnnp.70.5.574. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Forbes R. B., Lees A., Waugh N., Swingler R. J. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis. BMJ. 1999 Dec 11;319(7224):1529–1533. doi: 10.1136/bmj.319.7224.1529. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jacobs L. D., Beck R. W., Simon J. H., Kinkel R. P., Brownscheidle C. M., Murray T. J., Simonian N. A., Slasor P. J., Sandrock A. W. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000 Sep 28;343(13):898–904. doi: 10.1056/NEJM200009283431301. [DOI] [PubMed] [Google Scholar]
- Jacobs L. D., Cookfair D. L., Rudick R. A., Herndon R. M., Richert J. R., Salazar A. M., Fischer J. S., Goodkin D. E., Granger C. V., Simon J. H. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol. 1996 Mar;39(3):285–294. doi: 10.1002/ana.410390304. [DOI] [PubMed] [Google Scholar]
- Johnson K. P., Brooks B. R., Cohen J. A., Ford C. C., Goldstein J., Lisak R. P., Myers L. W., Panitch H. S., Rose J. W., Schiffer R. B. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995 Jul;45(7):1268–1276. doi: 10.1212/wnl.45.7.1268. [DOI] [PubMed] [Google Scholar]
- Li D. K., Zhao G. J., Paty D. W., University of British Columbia MS/MRI Analysis Research Group. The SPECTRIMS Study Group Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology. 2001 Jun 12;56(11):1505–1513. doi: 10.1212/wnl.56.11.1505. [DOI] [PubMed] [Google Scholar]
- Rice G., Ebers G. Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease? Arch Neurol. 1998 Dec;55(12):1578–1580. doi: 10.1001/archneur.55.12.1578. [DOI] [PubMed] [Google Scholar]
- Schwid S. R., Bever C. T., Jr The cost of delaying treatment in multiple sclerosis: what is lost is not regained. Neurology. 2001 Jun 26;56(12):1620–1620. doi: 10.1212/wnl.56.12.1620. [DOI] [PubMed] [Google Scholar]